Targeting the mitochondrial apoptotic pathway: a preferred approach in hematologic malignancies?
Authors:
Open Access
- 6 March 2014
- journal article
- review article
- Published by Springer Nature in Cell Death & Disease
- Vol. 5 (3) , e1098
Abstract
Acquired resistance toward apoptosis represents one of the hallmarks of human cancer and a major cause of the inefficacy of most anticancer treatment regimens. Based on its ability to inhibit apoptosis, the B-cell lymphoma/leukemia 2 (Bcl-2) protein family has garnered the most attention as a promising therapeutic target in cancer. Accordingly, efforts have lately been focused on the development of drugs targeting Bcl-2 proteins with considerable therapeutic success, particularly in hematologic malignancies. Here, we review the previous studies and highlight the pivotal role of the Bcl-2 protein family in the homeostasis of hematologic tissue compartment. This knowledge provides more insight into why some cancers are more sensitive to Bcl-2 targeting than others and will foster the clinical evaluation of Bcl-2-targeting strategies in cancer by avoiding severe on-target side effects in the development of healthy tissues.Keywords
This publication has 148 references indexed in Scilit:
- Genetically defining the mechanism of Puma- and Bim-induced apoptosisCell Death & Differentiation, 2011
- The histone deacetylase inhibitor entinostat (SNDX-275) induces apoptosis in Hodgkin lymphoma cells and synergizes with Bcl-2 family inhibitorsExperimental Hematology, 2011
- Molecular analysis of neutrophil spontaneous apoptosis reveals a strong role for the pro-apoptotic BH3-only protein NoxaCell Death & Differentiation, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activityThe Lancet Oncology, 2010
- Puma and to a lesser extent Noxa are suppressors of Myc-induced lymphomagenesisCell Death & Differentiation, 2009
- Bim and Bmf in tissue homeostasis and malignant diseaseOncogene, 2008
- Bcl-2-regulated apoptosis: mechanism and therapeutic potentialCurrent Opinion in Immunology, 2007
- The Bcl-2 apoptotic switch in cancer development and therapyOncogene, 2007
- Bim and Bad mediate imatinib-induced killing of Bcr/Abl + leukemic cells, and resistance due to their loss is overcome by a BH3 mimeticProceedings of the National Academy of Sciences, 2006